Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

Abstract

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

Keywords

Hypercholesterolaemia cardiovascular prevention

Get full access to this article

View all access options for this article.

References

Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Epub ahead of print 12 November 2013.

ACC/AHA. 2013 Prevention Guidelines ASCVD Risk Estimator. http://www.cardiosource.org/science-and-quality/practice-guidelines-and-quality-standards/2013-prevention-guideline-tools.aspx (2013, accessed 18 February 2014).

International Task Force for Prevention of Coronary Heart Disease, International Atherosclorosis Society. 2009 guide to prevention of coronary heart disease. Barcelona, Spain: Prous Science, SAU, 2009.

Reiner

Catapano

De Backer

. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.

Ray

Kastelein

Boekholdt

. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35: 960–968.

Jacobson

Ito

Maki

. National Lipid Association recommendations for patient-centered management of dyslipidemia. Part 1 – executive summary. J Clin Lipidol 2014; 8: 473–488.

Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia – full report. J Clin Lipidol 2014; 8: 29–60.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

Grundy

Cleeman

Merz

. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.

10.

American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014; 37(Suppl. 1): S14–S80.

11.

LaRosa

Grundy

Waters

. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

12.

Cannon

Braunwald

McCabe

. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.

13.

Cholesterol Treatment Trialists Collaboration, Baigent

Blackwell

. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

14.

Cohen

Boerwinkle

Mosley

Jr . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.

15.

Puri

Nissen

Shao

. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J 2013; 34: 3182–3190.

16.

Muntner

Colantonio

Cushman

. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014; 311: 1406–1415.

17.

Ridker

Cook

. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013; 382: 1762–1765.

18.

Kavousi

Leening

Nanchen

. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311: 1416–1423.

19.

Pencina

Navar-Boggan

D’Agostino

Sr . Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014; 370: 1422–1431.

20.

Amin NP, Martin SS, Blaha MJ, et al. Headed in the right direction but at risk for miscalculation: A critical appraisal of the 2013 ACC/AHA Risk Assessment Guidelines. J Am Coll Cardiol 2014; 63: 2789–2794.

21.

Finegold

Manisty

Goldacre

. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464–474.

22.

Sattar

Preiss

Murray

. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735–742.

23.

Preiss

Seshasai

Welsh

. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556–2564.

24.

Sattar

Ginsberg

Ray

. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atheroscler Suppl 2014; 15: 1–15.

25.

Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: Gluttony in the time of statins? JAMA Intern Med 2014; 174: 1038–1045.

26.

Ong

Waters

Messig

. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol 2014; 113: 1593–1598.

27.

Zethelius

Gudbjörnsdottir

Eliasson

. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 daiabetes: Report from the Swedish National Diabetes Register. Eur J Prev Cardiol 2014; 21: 244–252.

28.

Gibbs

Brancati

Chen

. for the Look AHEAD Research Group). Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur J Prev Cardiol 2014; 21: 608–617.